SWITCHING OUT OF CLASS OR TO ANOTHER ANTI-TNF AGENT IS THE BEST STRATEGY FOR CLINICAL EFFICACY AND TREATMENT PERSISTENCE IN IBD PATIENTS WITH ANTI-DRUG ANTIBODIES AGAINST ANTI-TNF

被引：0
|
作者：
Anjie, Suzanne I.
Hanzel, Jurij
Gecse, Krisztina B.
D'Haens, Geert
Brandse, Johannan F.
机构：
来源：
GASTROENTEROLOGY | 2023年 / 164卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Tu1774
引用
收藏
页码：S1120 / S1121
页数：2
相关论文
共 50 条
  • [1] Switching out of class or to another anti-TNF agent is the most effective strategy in IBD patients with immunogenicity against anti-TNF antibodies
    Anjie, S.
    Hanzel, J.
    Gecse, K. B.
    D'Haens, G. R.
    Brandse, J. F.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 803 - 803
  • [2] INCREASED RISK OF ANTI-DRUG ANTIBODIES TO A SECOND ANTI-TNF IN PATIENTS WHO DEVELOPED ANTIBODIES TO THE FIRST ANTI-TNF
    Yanai, Henit A.
    Amir, Shira
    Avni-Biron, Irit
    Perets, Tsachi Tsadok
    Shamir, Raanan
    Dotan, Iris
    Assa, Amit
    GASTROENTEROLOGY, 2020, 158 (06) : S671 - S671
  • [3] Increased risk of anti-drug antibodies to a second anti-TNF in patients who developed antibodies to the first anti-TNF
    Yanai, H.
    Amir, S.
    Biron, I. Avni
    Perets, T. Tsadok
    Shamir, R.
    Dotan, I.
    Assa, A.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S439 - S439
  • [4] ANTI-DRUG ANTIBODIES, DRUG LEVELS AND CLINICAL EFFICACY OF THE ANTI-TNF BIOLOGICS IN RHEUMATIC DISEASES
    Mok, C. C.
    van der Kleij, D.
    Wolbink, G.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 226 - 226
  • [5] Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNFα biologics in rheumatic diseases
    Mok, C. C.
    van der Kleij, D.
    Wolbink, G. J.
    CLINICAL RHEUMATOLOGY, 2013, 32 (10) : 1429 - 1435
  • [6] Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNFα biologics in rheumatic diseases
    C. C. Mok
    D. van der Kleij
    G. J. Wolbink
    Clinical Rheumatology, 2013, 32 : 1429 - 1435
  • [7] OUTCOMES AND ECONOMIC IMPACT OF SWITCHING FROM ANTI-TNF TO ANTI-TNF THERAPY COMPARED WITH SWITCHING FROM ANTI-TNF TO VEDOLIZUMAB THERAPY IN PATIENTS WITH IBD
    Chiorean, Michael V.
    Afzali, Anita
    Zhou, Zhou
    Macaulay, Dendy
    Rizzo, Joanne
    Skup, Martha
    Wang, Anthony
    GASTROENTEROLOGY, 2017, 152 (05) : S591 - S591
  • [8] INTEREST IN THE ADDITION OF AZATHIOPRINE (AZA) TO THE SWITCH OF ANTI-TNF IN IBD PATIENTS IN CLINICAL RELAPSE WITH UNDETECTABLE ANTI-TNF TROUGH LEVELS AND ANTI-DRUG ANTIBODIES: A PROSPECTIVE RANDOMIZED TRIAL
    Roblin, Xavier
    Paul, Stephane
    Nancey, Stephane
    Williet, Nicolas
    Flourie, Bernard
    GASTROENTEROLOGY, 2018, 154 (06) : S84 - S84
  • [9] BARRIERS AGAINST TESTING ANTI-TNF DRUG LEVELS AND ANTI-DRUG ANTIBODIES IN ROUTINE CLINICAL PRACTICE
    Gavan, S. P.
    Daker-White, G.
    Payne, K.
    Barton, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1726 - 1727
  • [10] ANTI-DRUG ANTIBODIES AS A PREDICTOR FOR THE DISCONTINUATION OF ANTI-TNF AGENTS IN PATIENTS WITH SPONDYLOARTHRTIS
    Kim, H. J.
    Hwang, J.
    Kim, I.
    Jeong, H.
    Lee, J.
    Jeon, C. H.
    Koh, E. -M.
    Cha, H. -S.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 717 - 718
12345